Jorge J. Palop

This study shows that reducing tau mitigates transcriptomic and behavioral issues in an Alzheimer's model without affecting amyloid levels.

This study shows that blocking fibrin-induced microglia activation reduces neuronal hyperactivity and restores the neuroimmune interactome in Alzheimer's disease.

This study shows that blocking fibrin-microglia interactions reduces AD-related brain network dysfunction and behavioral issues in mice.

This paper investigates sleep and activity patterns in a mouse model of early onset Alzheimer's disease, finding a long wake/short sleep phenotype more pronounced in females.

This study identifies cGAS-mediated IFN-I signaling as a driver of disease progression in drug-refractory epilepsy, showing that targeting cGAS reduces epileptic phenotypes and inflammation.

The paper introduces a labyrinth paradigm and probabilistic modeling framework to study hidden navigational states in mice, revealing impaired states in an Alzheimer's model and linking them to gamma oscillations in the PPC.

This study investigates how APOE4 and Aβ interact in preclinical Alzheimer's disease, finding their synergistic effects on neuronal proteostasis and network dysfunction.

This study shows that exposure to anti-GluN1 mAb during development causes long-term sensory-motor deficits and callosal axon changes in mice.

The paper develops human MGE-pINs from pluripotent stem cells and shows their maturation into SST and PVALB subtypes with functional and molecular characteristics.

The paper introduces CrAAVe-seq, an AAV-based CRISPR screening platform for in vivo cell type-specific analysis, demonstrating its scalability and sensitivity in identifying neuron-essential genes.

The paper introduces VAME, a deep learning framework for identifying hierarchical behavioral structures from animal motion data, demonstrating its ability to detect discrete motifs and community-specific usage patterns in mouse models.

The paper shows that small-molecule ketone esters reduce epileptiform discharges and improve cognition in an Alzheimer's disease mouse model.

This study shows that a ketogenic diet and beta-hydroxybutyrate reduce epileptiform spikes, improve memory, and increase survival in Alzheimer's mouse models.